Holen Sie sich die Stockscreener-App
17.77
2.33%
0.42
Schlusskurs vom Vortag:
$17.35
Offen:
$17.29
24-Stunden-Volumen:
39,249
Relative Volume:
0.24
Marktkapitalisierung:
$805.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+10.69%
1M Leistung:
+29.69%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$16.14
$17.96
1-Wochen-Bereich:
$14.35
$17.96
52-Wochen-Spanne:
$7.255
$24.90
Sionna Therapeutics Inc Stock (SION) Company Profile
Firmenname
Sionna Therapeutics Inc
Sektor
Branche
Telefon
617-819-2020
Adresse
21 HICKORY DRIVE, SUITE 500, WALTHAM
Vergleichen Sie SION mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
17.75 | 805.12M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.22 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.79 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.49 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
555.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.53 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Eingeleitet | Guggenheim | Buy |
| 2025-03-04 | Eingeleitet | Stifel | Buy |
| 2025-03-04 | Eingeleitet | TD Cowen | Buy |
Sionna Therapeutics Inc Aktie (SION) Neueste Nachrichten
Sling Therapeutics, Inc. Appoints Ken Lock as Chief Commercial Officer - MarketScreener
Sionna Therapeutics reports annual meeting results By Investing.com - Investing.com South Africa
Sionna Therapeutics Holds Annual Stockholders Meeting - TipRanks
Sionna Therapeutics reports annual meeting results - Investing.com
Sionna's experimental CFTR modulators show promise in preclinical tests - Cystic Fibrosis News Today
Odyssey Therapeutics pulls plug on IPO plans - The Business Journals
Odyssey Ends Quest for Nasdaq, Pulls IPO Application After Nearly 5 Months - BioSpace
Odyssey pulls back from IPO plans as public markets remain frozen - Endpoints News
Sionna Therapeutics advances CF treatment with new data By Investing.com - Investing.com South Africa
Sionna Therapeutics advances CF treatment with new data - Investing.com India
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model - GlobeNewswire
Breakthrough Clinical Data: New Dual Therapy Achieves Complete CFTR Correction in Cystic Fibrosis Model - Stock Titan
NBD1 stabilizers safe in healthy volunteers, Sionna says - Cystic Fibrosis News Today
Petri Dish: PepGen halts work on Duchenne drug; Needham biotech announces layoffs - The Business Journals
2 Soaring Stocks Wth More Upside Potential - AOL.com
Transcript : Sionna Therapeutics, Inc.Special Call - marketscreener.com
Sionna advances cystic fibrosis treatments to new trials By Investing.com - Investing.com South Africa
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial - Benzinga
Stifel analysts reiterate buy rating on Sionna Therapeutics stock By Investing.com - Investing.com Canada
Sionna Therapeutics Announces Positive Phase 1 Results For SION-719, SION-451 In Cystic Fibrosis - Nasdaq
Sionna advances cystic fibrosis treatments to new trials - Investing.com Australia
Sionna Therapeutics Reports Positive Phase 1 Trial Results - TipRanks
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis - The Manila Times
Sionna Therapeutics Announces Positive Phase 1 Data For Nbd1 Stabilizers Sion-719 And Sion-451 And Advances Both Programs In Clinical Development For Cystic Fibrosis - marketscreener.com
Sionna Therapeutics Announces Positive Phase 1 Data for - GlobeNewswire
Sionna selects which cystic fibrosis drug it will study in a mid-stage test - Endpoints News
Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
3 No-Brainer Healthcare Stocks to Buy in June - AOL.com
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 6% – Here’s What Happened - Defense World
Why Summit Therapeutics Plunged Today - AOL.com
3 High-Flying Stocks That Could Soar Even More - AOL.com
Sionna Therapeutics to Present Preclinical Data on CFTR Modulators at European Cystic Fibrosis Conference - Nasdaq
Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference - GlobeNewswire
Sionna Therapeutics (NASDAQ:SION) Shares Gap Down Following Weak Earnings - Defense World
Sionna Therapeutics Phase 1 Topline Data For Nbd1 Stabilizers Sion-719 & Sion-451 Expected This Quarter - marketscreener.com
Sionna Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
Private equity firms invested in Sionna Therapeutics, Inc. (NASDAQ:SION) copped the brunt of last week's US$56m market cap decline - simplywall.st
While individual investors own 26% of Sionna Therapeutics, Inc. (NASDAQ:SION), private equity firms are its largest shareholders with 56% ownership - Yahoo Finance
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - AOL.com
Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 - The Manila Times
Revolutionary Cystic Fibrosis Treatment Developer Sionna Takes Stage at Major Healthcare Conference - Stock Titan
2 Beaten-Down Stocks With Incredible Upside Potential - AOL.com
OrbiMed-backed biotech looks to challenge Vertex in cystic fibrosis by 'drugging the undruggable' - Endpoints News
Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
In 2025, biotech IPOs were supposed to bounce back. It hasn't happened yet. - The Business Journals
Sionna Therapeutics (NASDAQ:SION) Trading Down 4.2%What's Next? - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Reaches New 1-Year Low on Disappointing Earnings - Defense World
Stifel maintains Buy rating on Sionna Therapeutics stock at $32 target - Investing.com Australia
Finanzdaten der Sionna Therapeutics Inc-Aktie (SION)
Es liegen keine Finanzdaten für Sionna Therapeutics Inc (SION) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Sionna Therapeutics Inc-Aktie (SION) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Feb 10 '25 |
Buy |
18.00 |
1,125,000 |
20,250,000 |
6,923,365 |
| ORBIMED ADVISORS LLC | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Thompson Peter A. | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Booth Bruce | Director |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
1.40%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):